Myriad Genetics (MYGN) Income from Continuing Operations (2009 - 2026)
Myriad Genetics (MYGN) reported Income from Continuing Operations of 34100000.0 for Q1 2026, down 34000.0% year-over-year from N/an in Q1 2025, and down 331.65% quarter-over-quarter from 7900000.0 in Q4 2025.
Myriad Genetics (MYGN) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Myriad Genetics (MYGN) has 18 years of Income from Continuing Operations data on file, last reported at 34100000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 34100000.0, down 34000.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 399900000.0 (down 294.38% YoY), and the FY2025 annual result was 365900000.0, down 187.43% from the prior year.
- Income from Continuing Operations eased to 34100000.0 in Q1 2026 per MYGN's latest filing, from 7900000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 100000.0 in Q1 2025 and troughed at 330500000.0 in Q2 2025.
- A 5-year average of 53094117.65 and a median of 34100000.0 in 2026 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations surged 99.62% in 2025, then plunged 34000.0% in 2026.
- A 5-year view of Income from Continuing Operations shows it stood at 42300000.0 in 2022, then rose by 26.24% to 31200000.0 in 2023, then tumbled by 36.22% to 42500000.0 in 2024, then soared by 81.41% to 7900000.0 in 2025, then sank by 331.65% to 34100000.0 in 2026.
- Business Quant data shows MYGN's Income from Continuing Operations at 34100000.0 in Q1 2026, 7900000.0 in Q4 2025, and 27400000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Waters | 29,902.70 Bn | 29,902.24 Bn | 1.11 Bn | -72.00 Mn |
| 2 | Thermo Fisher Scientific | 175.99 Bn | 172.74 Bn | 7.74 Bn | 1.66 Bn |
| 3 | Danaher | 129.87 Bn | 124.18 Bn | 3.59 Bn | 1.03 Bn |
| 4 | Idexx Laboratories | 44.75 Bn | 44.55 Bn | 722.74 Mn | 278.45 Mn |
| 5 | Agilent Technologies | 37.52 Bn | 35.72 Bn | 990.00 Mn | 339.00 Mn |
| 6 | Iqvia Holdings | 30.91 Bn | 28.94 Bn | 1.36 Bn | 269.00 Mn |
| 7 | Natera | 30.21 Bn | 29.11 Bn | 696.04 Mn | -85.11 Mn |
| 8 | Illumina | 24.19 Bn | 23.04 Bn | 721.00 Mn | 134.00 Mn |
| 9 | Mettler Toledo International | 23.12 Bn | 23.06 Bn | 555.82 Mn | 169.45 Mn |
| 10 | Myriad Genetics | 411.34 Mn | 286.94 Mn | 137.60 Mn | -34.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.10 Mn |
| Dec 31, 2025 | -7.90 Mn |
| Sep 30, 2025 | -27.40 Mn |
| Jun 30, 2025 | -330.50 Mn |
| Mar 31, 2025 | -100,000.00 |
| Dec 31, 2024 | -42.50 Mn |
| Sep 30, 2024 | -22.10 Mn |
| Jun 30, 2024 | -36.70 Mn |
| Mar 31, 2024 | -26.00 Mn |
| Dec 31, 2023 | -31.20 Mn |
| Sep 30, 2023 | -61.30 Mn |
| Jun 30, 2023 | -116.10 Mn |
| Mar 31, 2023 | -54.70 Mn |
| Dec 31, 2022 | -42.30 Mn |
| Sep 30, 2022 | -35.10 Mn |
| Jun 30, 2022 | -14.10 Mn |
| Mar 31, 2022 | -20.50 Mn |
| Dec 31, 2021 | -7.60 Mn |
| Sep 30, 2021 | 24.60 Mn |
| Jun 30, 2021 | -4.70 Mn |